Table 2.

Ovarian cancer–specific mortality by relative telomere length z score quartiles among patients with ovarian cancer

Reference modela HRMultivariate model HRb
Relative TL z score(95% CI)P(95% CI)P
Quartile 11.00 (ref)1.00 (ref)
Quartile 20.79 (0.60–1.02)0.070.80 (0.60–1.05)0.11
Quartile 30.90 (0.69–1.17)0.430.94 (0.71–1.25)0.66
Quartile 40.88 (0.67–1.07)0.350.92 (0.69–1.23)0.57
Quartile 2+3+40.85 (0.69–1.05)0.130.88 (0.77–1.10)0.25
Ptrend0.97 (0.89–1.06)0.550.99 (0.90–1.09)0.83
Serous tumors
Quartile 11.00 (ref)1.00 (ref)
Quartile 20.90 (0.67–1.23)0.500.88 (0.63–1.23)0.47
Quartile 30.86 (0.63–1.18)0.360.84 (0.60–1.17)0.29
Quartile 40.88 (0.64–1.20)0.420.87 (0.62–1.22)0.41
Quartile 2+3+40.88 (0.68–1.14)0.330.86 (0.66–1.13)0.28
Ptrend0.96 (0.88–1.06)0.400.95 (0.85–1.06)0.38
Nonserous tumors
Quartile 11.00 (ref)1.00 (ref)
Quartile 20.89 (0.53–1.51)0.670.97 (0.55–1.70)0.91
Quartile 31.19 (0.71–1.98)0.511.33 (0.76–2.33)0.32
Quartile 40.98 (0.56–1.70)0.941.13 (0.63–2.03)0.67
Quartile 2+3+41.01 (0.66–1.55)0.961.13 (0.71–1.79)0.62
Ptrend1.03 (0.86–1.22)0.771.04 (0.45–2.41)0.92
  • aReference HR adjusted for age at blood draw (continuous), batch (batch 1 and batch 2) and stage (I, II, III, and IV).

  • bMultivariate HR adjusted for age at blood draw (continuous), batch (batch 1 and batch 2), stage (I, II, III, and IV), age at diagnosis (continuous), BRCA mutation status (carrier/noncarrier), histologic subtype (serous, mucinous, endometrioid, and other), body mass index 5 years before the cancer diagnosis (continuous), smoking history (ever/never), and chemotherapy (yes/no).